A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia

Schizophrenia Clinical Trial

Official title:

A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05039489
• Other study ID #: 82171508
• Status: Recruiting
• Phase: N/A
• Start date: September 9, 2021
• Est. completion date: November 30, 2023

Study information

• Verified date: September 2021
• Source: Central South University
• Contact: Wenbin Guo
• Phone: +8613875936768
• Email: guowenbin76[@]csu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is dedicated to exploring the brain mechanism of medication-resistant auditory hallucinations and developing effective treatment methods for them by using both cross-sectional and longitudinal designs. The continuous theta burst stimulation(cTBS) treatment mode, with the left cerebellum Crus II as the stimulation target, is applied to treat the schizophrenia patients with the medication-resistant auditory hallucinations. At the same time, the first-episode schizophrenia patients with auditory hallucinations were recruited as a test cohort to examine that brain mechanism of general auditory hallucinations in schizophrenia may be the structural and functional abnormalities in the temporoparietal circuit.

Description:

Previous studies have shown that repetitive transcranial magnetic stimulation (rTMS) targeted at the temporal-parietal junction can effectively treat genenal auditory hallucinations in schizophrenia, but it is not the case for medication-resistant auditory hallucinations. Studies suggested that rTMS targeted at the left Crus II might be effective for medication-resistant auditory hallucinations. This study is dedicated to exploring the brain mechanism of medication-resistant auditory hallucinations and developing effective treatment methods for them by using both cross-sectional and longitudinal designs. The continuous theta burst stimulation(cTBS) treatment mode, with the left cerebellum Crus II as the stimulation target, is applied to treat the schizophrenia patients with the medication-resistant auditory hallucinations. Assessment with symptomatology, neuropsychology, neuroimaging, and machine learning methods is utilized to examine the investigators hypothesis that structural and functional abnormalities of the cerebral cortico-cerebellar-thalamic-cortical circuit (CCTCC) may contribute to brain mechanism of medication-resistant auditory hallucinations in schizophrenia. At the same time, the first-episode schizophrenia patients with auditory hallucinations were recruited as a test cohort to examine that brain mechanism of general auditory hallucinations in schizophrenia may be the structural and functional abnormalities in the temporoparietal circuit, whereas structural and functional abnormalities of the CCTCC may contribute to brain mechanism of medication-resistant auditory hallucinations in schizophrenia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: November 30, 2023
• Est. primary completion date: October 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Written informed consent

2. 18-45 years old, right-handed

3. Meet the diagnostic criteria for schizophrenia according to the Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)

4. After a sufficient course of antipsychotic treatment (more than 6 weeks, two or more antipsychotic drugs, at least one of which is the second generation of atypical antipsychotic drugs), auditory hallucinations occurred more than 5 times a day for more than 6 months

5. Stable antipsychotic medication 4 weeks before and during the treatment (except auditory hallucination symptoms)

Exclusion Criteria:

1. A history of epilepsy, convulsions, stroke or other serious brain diseases

2. There are serious infectious diseases, malignant tumors, and severe somatic comorbidity

3. Mental retardation, personality disorder and so on

4. Contraindications for magnetic resonance imaging

5. Diagnose of substance dependence or abuse as primary clinical problem

6. Pregnancy

7. Participants had received Modified Electraconvulsive Therapy (MECT) or TMS treatment in recent 6 months

Related Conditions & MeSH terms

• Hallucinations
• Schizophrenia

Intervention

Drug:
• Antipsychotic drugs
Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs

Device:
• cTBS(the left temporoparietal cortex as the stimulation target)
Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
• cTBS (the left cerebellum Crus II as the stimulation target)
Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks

Locations

Country	Name	City	State
China	The Second Xiangya Hospital of Central South University	Changsha

Sponsors (1)

Lead Sponsor	Collaborator
Central South University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psychotic Symptom Rating Scales-Auditory Hallucination Subscale (PSYRATS-AH)	The Psychotic Symptom Rating Scales-Auditory Hallucination Subscale (PSYRATS-AH) is an instrument designed to quantify the severity of hallucinations before and after treatment at different follow up point. Raw score range is 0-44. A higher score indicates a worse outcome.	From baseline to 10 weeks
Primary	Structural and Function MRI data	A 3.0 T Siemens scanner was used to obtain the fMRI images in the Second Xiangya Hospital of Central South University.The MRI data wii be obtained before and after treatment at different follow up point.	From baseline to 10 weeks
Primary	Positive and Negative Syndrome Scale (PANSS)	The PANSS total scores, subscale scores were used to evaluate the severity of psychotic symptoms for schizophrenia before and after treatment at different follow up point.The total score of the PANSS was more than 60.The higher scores mean a worse outcome.	From baseline to 10 weeks
Secondary	Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)	Pre-post assessment of cognitive function via Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)	From baseline to 10 weeks
Secondary	The Stroop test	Pre-post assessment of cognitive function via the Stroop test	From baseline to 10 weeks
Secondary	Wisconsin Card Sorting Test (WCST)	Pre-post assessment of cognitive function via Wisconsin Card Sorting Test (WCST)	From baseline to 10 weeks